CO5611134A2 - Composiciones farmaceuticas que contienen sales de tiotropio y nuevos agentes inhibidores de la cinasa egfr - Google Patents

Composiciones farmaceuticas que contienen sales de tiotropio y nuevos agentes inhibidores de la cinasa egfr

Info

Publication number
CO5611134A2
CO5611134A2 CO04090723A CO04090723A CO5611134A2 CO 5611134 A2 CO5611134 A2 CO 5611134A2 CO 04090723 A CO04090723 A CO 04090723A CO 04090723 A CO04090723 A CO 04090723A CO 5611134 A2 CO5611134 A2 CO 5611134A2
Authority
CO
Colombia
Prior art keywords
salts
egfr
possibly
tiotropal
cinase
Prior art date
Application number
CO04090723A
Other languages
English (en)
Inventor
Birgit Jung
Michel Pairet
Michael Pairet
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of CO5611134A2 publication Critical patent/CO5611134A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

1.- Medicamento, caracterizado por un cierto contenido de uno o varios agentes anticolinérgicos (1) en combinación con uno o varios agentes inhibidores de la cinasa del EGFR (2) eventualmente en forma de sus enantiómeros, de mezclas de los enantiómeros o en forma de los racematos, eventualmente en forma de los solvatos o hidratos así como eventualmente en común con una sustancia auxiliar farmacéuticamente compatible.2.- Medicamento según la reivindicación 1, caracterizado porque las sustancias activas 1 y 2 están contenidas ya sea en común en una forma de presentación o en dos formas de presentación separadas.3.- Medicamento según una de las reivindicaciones 1 ó 2, caracterizado porque la sustancia activa 1 se selecciona entre el conjunto que consta de sales de tiotropio, sales de oxitropio o sales de ipratropio, de un modo preferido sales de tiotropio.4.- Medicamento según una de las reivindicaciones 1 a 3, caracterizado porque la sustancia activa 1 está contenida en forma del cloruro, bromuro, yoduro, metano-sulfonato, para-tolueno-sulfonato o metil-sulfato, de un modo preferido en forma del bromuro.
CO04090723A 2002-02-16 2004-09-13 Composiciones farmaceuticas que contienen sales de tiotropio y nuevos agentes inhibidores de la cinasa egfr CO5611134A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10206505A DE10206505A1 (de) 2002-02-16 2002-02-16 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern

Publications (1)

Publication Number Publication Date
CO5611134A2 true CO5611134A2 (es) 2006-02-28

Family

ID=27635037

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04090723A CO5611134A2 (es) 2002-02-16 2004-09-13 Composiciones farmaceuticas que contienen sales de tiotropio y nuevos agentes inhibidores de la cinasa egfr

Country Status (21)

Country Link
EP (1) EP1478398B1 (es)
JP (1) JP2005517039A (es)
KR (1) KR20040083519A (es)
CN (1) CN1633305A (es)
AR (1) AR038494A1 (es)
AT (1) ATE430581T1 (es)
AU (1) AU2003206881B2 (es)
BR (1) BR0307703A (es)
CA (1) CA2476127C (es)
CO (1) CO5611134A2 (es)
DE (2) DE10206505A1 (es)
ES (1) ES2326968T3 (es)
MX (1) MXPA04007813A (es)
NZ (1) NZ535166A (es)
PE (1) PE20030859A1 (es)
PL (1) PL369736A1 (es)
RU (1) RU2004127869A (es)
TW (1) TW200400036A (es)
UY (1) UY27670A1 (es)
WO (1) WO2003068264A1 (es)
ZA (1) ZA200404787B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230751A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern
DE102004001607A1 (de) * 2004-01-09 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen auf der Basis von Scopin- oder Tropensäureestern mit EGFR-Kinase-Hemmern
US20060035893A1 (en) * 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP1957468A2 (en) * 2005-09-06 2008-08-20 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4 - (phenylamino)quinazolines useful as irreversible inhibitors of epidermal growth factor receptor tyrosine kinase
KR100832594B1 (ko) 2005-11-08 2008-05-27 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
CN102264745B (zh) 2008-11-10 2015-07-22 财团法人卫生研究院 作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物
US20120220557A1 (en) * 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
US10710968B2 (en) 2016-01-13 2020-07-14 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042062A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung

Also Published As

Publication number Publication date
JP2005517039A (ja) 2005-06-09
CA2476127A1 (en) 2003-08-21
EP1478398B1 (de) 2009-05-06
EP1478398A1 (de) 2004-11-24
CN1633305A (zh) 2005-06-29
WO2003068264A1 (de) 2003-08-21
UY27670A1 (es) 2003-09-30
ATE430581T1 (de) 2009-05-15
MXPA04007813A (es) 2004-10-15
AR038494A1 (es) 2005-01-19
DE50311496D1 (de) 2009-06-18
PL369736A1 (en) 2005-05-02
AU2003206881B2 (en) 2009-02-26
CA2476127C (en) 2011-06-14
DE10206505A1 (de) 2003-08-28
TW200400036A (en) 2004-01-01
BR0307703A (pt) 2005-01-04
ES2326968T3 (es) 2009-10-22
RU2004127869A (ru) 2005-08-27
AU2003206881A1 (en) 2003-09-04
ZA200404787B (en) 2005-08-11
NZ535166A (en) 2007-01-26
PE20030859A1 (es) 2003-11-18
KR20040083519A (ko) 2004-10-02

Similar Documents

Publication Publication Date Title
EA200702498A1 (ru) N-(пиридин-2-ил)сульфонамидные производные
AR039273A1 (es) Composiciones farmaceuticas basadas en anticolinergicos e inhibidores de la p38 quinasa
AR054688A1 (es) Alquil-piridinas como inhibidores 11-beta de la diabetes
ECSP078003A (es) Inhibidores de aspartil proteasas
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
PE20081649A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
ECSP055738A (es) PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
TW200732324A (en) Novel compounds that are ERK inhibitors
UY28132A1 (es) Derivados de pirrolopirimidina
AR053186A1 (es) Derivados del 1- bencil indol carboxamida
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
TW200745089A (en) Novel compounds that are ERK inhibitors
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
ECSP034914A (es) "azaindoles"
EA200401056A1 (ru) Комбинация, содержащая производные тропана, полезные в терапии
AR064619A1 (es) Derivados de amino-imidazopiridinas, composiciones farmaceuticas que los contienen y usos de los mismos como agentes antitumorales.
ES2187983T3 (es) Derivados 1,2,3,4-tetrahidronaftaleno sustituidos.
CO5611134A2 (es) Composiciones farmaceuticas que contienen sales de tiotropio y nuevos agentes inhibidores de la cinasa egfr
PE20120642A1 (es) Formulacion en lipidos estabilizada de un promotor de la apoptosis
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1

Legal Events

Date Code Title Description
FG Application granted